Cardiac involvement in systemic rheumatic diseases: An update

Piercarlo Sarzi-Puttini, Fabiola Atzeni, Roberto Gerli, Elena Bartoloni, Andrea Doria, Tatiana Barskova, Marco Matucci-Cerinic, Simona Sitia, Livio Tomasoni, Maurizio Turiel

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The high rates of cardiovascular (CV) mortality and morbidity observed in patients with systemic autoimmune diseases (SADs) cannot be fully explained by traditional atherosclerosis risk factors as standard therapy (i.e. corticosteroids and methotrexate), cytokines and disease activity may all contribute to accelerated atherosclerosis. There is considerable evidence showing that chronic inflammation and immune dysregulation play a pathogenetic role in the development of atherosclerosis in patients with SADs. Chronic inflammation, accelerated atherosclerosis and functional abnormalities of the endothelium suggest that subclinical CV involvement begins soon after the onset of the disease and progresses with disease duration. All cardiac structures may be affected during the course of SADs (valves, the conduction system, the myocardium, endocardium and pericardium, and coronary arteries), and the cardiac complications have a variety of clinical manifestations. As these are all associated with an unfavourable prognosis, it is essential to detect subclinical cardiac involvement in asymptomatic SAD patients, and begin adequate management and treatment early.

Original languageEnglish
Pages (from-to)849-852
Number of pages4
JournalAutoimmunity Reviews
Volume9
Issue number12
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Rheumatic Diseases
Autoimmune Diseases
Atherosclerosis
Inflammation
Endocardium
Pericardium
Methotrexate
Endothelium
Coronary Vessels
Myocardium
Adrenal Cortex Hormones
Cytokines
Morbidity
Mortality
Therapeutics

Keywords

  • Atherosclerosis
  • Autoimmune diseases
  • Heart
  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Systemic sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Sarzi-Puttini, P., Atzeni, F., Gerli, R., Bartoloni, E., Doria, A., Barskova, T., ... Turiel, M. (2010). Cardiac involvement in systemic rheumatic diseases: An update. Autoimmunity Reviews, 9(12), 849-852. https://doi.org/10.1016/j.autrev.2010.08.002

Cardiac involvement in systemic rheumatic diseases : An update. / Sarzi-Puttini, Piercarlo; Atzeni, Fabiola; Gerli, Roberto; Bartoloni, Elena; Doria, Andrea; Barskova, Tatiana; Matucci-Cerinic, Marco; Sitia, Simona; Tomasoni, Livio; Turiel, Maurizio.

In: Autoimmunity Reviews, Vol. 9, No. 12, 10.2010, p. 849-852.

Research output: Contribution to journalArticle

Sarzi-Puttini, P, Atzeni, F, Gerli, R, Bartoloni, E, Doria, A, Barskova, T, Matucci-Cerinic, M, Sitia, S, Tomasoni, L & Turiel, M 2010, 'Cardiac involvement in systemic rheumatic diseases: An update', Autoimmunity Reviews, vol. 9, no. 12, pp. 849-852. https://doi.org/10.1016/j.autrev.2010.08.002
Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T et al. Cardiac involvement in systemic rheumatic diseases: An update. Autoimmunity Reviews. 2010 Oct;9(12):849-852. https://doi.org/10.1016/j.autrev.2010.08.002
Sarzi-Puttini, Piercarlo ; Atzeni, Fabiola ; Gerli, Roberto ; Bartoloni, Elena ; Doria, Andrea ; Barskova, Tatiana ; Matucci-Cerinic, Marco ; Sitia, Simona ; Tomasoni, Livio ; Turiel, Maurizio. / Cardiac involvement in systemic rheumatic diseases : An update. In: Autoimmunity Reviews. 2010 ; Vol. 9, No. 12. pp. 849-852.
@article{17effc3065014657aaeb20f532905a7c,
title = "Cardiac involvement in systemic rheumatic diseases: An update",
abstract = "The high rates of cardiovascular (CV) mortality and morbidity observed in patients with systemic autoimmune diseases (SADs) cannot be fully explained by traditional atherosclerosis risk factors as standard therapy (i.e. corticosteroids and methotrexate), cytokines and disease activity may all contribute to accelerated atherosclerosis. There is considerable evidence showing that chronic inflammation and immune dysregulation play a pathogenetic role in the development of atherosclerosis in patients with SADs. Chronic inflammation, accelerated atherosclerosis and functional abnormalities of the endothelium suggest that subclinical CV involvement begins soon after the onset of the disease and progresses with disease duration. All cardiac structures may be affected during the course of SADs (valves, the conduction system, the myocardium, endocardium and pericardium, and coronary arteries), and the cardiac complications have a variety of clinical manifestations. As these are all associated with an unfavourable prognosis, it is essential to detect subclinical cardiac involvement in asymptomatic SAD patients, and begin adequate management and treatment early.",
keywords = "Atherosclerosis, Autoimmune diseases, Heart, Rheumatoid arthritis, Systemic lupus erythematosus, Systemic sclerosis",
author = "Piercarlo Sarzi-Puttini and Fabiola Atzeni and Roberto Gerli and Elena Bartoloni and Andrea Doria and Tatiana Barskova and Marco Matucci-Cerinic and Simona Sitia and Livio Tomasoni and Maurizio Turiel",
year = "2010",
month = "10",
doi = "10.1016/j.autrev.2010.08.002",
language = "English",
volume = "9",
pages = "849--852",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Cardiac involvement in systemic rheumatic diseases

T2 - An update

AU - Sarzi-Puttini, Piercarlo

AU - Atzeni, Fabiola

AU - Gerli, Roberto

AU - Bartoloni, Elena

AU - Doria, Andrea

AU - Barskova, Tatiana

AU - Matucci-Cerinic, Marco

AU - Sitia, Simona

AU - Tomasoni, Livio

AU - Turiel, Maurizio

PY - 2010/10

Y1 - 2010/10

N2 - The high rates of cardiovascular (CV) mortality and morbidity observed in patients with systemic autoimmune diseases (SADs) cannot be fully explained by traditional atherosclerosis risk factors as standard therapy (i.e. corticosteroids and methotrexate), cytokines and disease activity may all contribute to accelerated atherosclerosis. There is considerable evidence showing that chronic inflammation and immune dysregulation play a pathogenetic role in the development of atherosclerosis in patients with SADs. Chronic inflammation, accelerated atherosclerosis and functional abnormalities of the endothelium suggest that subclinical CV involvement begins soon after the onset of the disease and progresses with disease duration. All cardiac structures may be affected during the course of SADs (valves, the conduction system, the myocardium, endocardium and pericardium, and coronary arteries), and the cardiac complications have a variety of clinical manifestations. As these are all associated with an unfavourable prognosis, it is essential to detect subclinical cardiac involvement in asymptomatic SAD patients, and begin adequate management and treatment early.

AB - The high rates of cardiovascular (CV) mortality and morbidity observed in patients with systemic autoimmune diseases (SADs) cannot be fully explained by traditional atherosclerosis risk factors as standard therapy (i.e. corticosteroids and methotrexate), cytokines and disease activity may all contribute to accelerated atherosclerosis. There is considerable evidence showing that chronic inflammation and immune dysregulation play a pathogenetic role in the development of atherosclerosis in patients with SADs. Chronic inflammation, accelerated atherosclerosis and functional abnormalities of the endothelium suggest that subclinical CV involvement begins soon after the onset of the disease and progresses with disease duration. All cardiac structures may be affected during the course of SADs (valves, the conduction system, the myocardium, endocardium and pericardium, and coronary arteries), and the cardiac complications have a variety of clinical manifestations. As these are all associated with an unfavourable prognosis, it is essential to detect subclinical cardiac involvement in asymptomatic SAD patients, and begin adequate management and treatment early.

KW - Atherosclerosis

KW - Autoimmune diseases

KW - Heart

KW - Rheumatoid arthritis

KW - Systemic lupus erythematosus

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=77956917813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956917813&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2010.08.002

DO - 10.1016/j.autrev.2010.08.002

M3 - Article

C2 - 20692379

AN - SCOPUS:77956917813

VL - 9

SP - 849

EP - 852

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 12

ER -